EyePoint, Inc. (EYPT) analyst actions
Rating and price-target actions on EYPT in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the EYPT overview →
2 measured EYPT analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against EyePoint, Inc. (EYPT) And Encourages Shareholders to Reach Out | Press release | +0.30% | +1.33% | |
| EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema | Press release | -4.67% | -13.05% |
Keep exploring
More EYPT: earnings → · SEC filings → · EYPT overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Catalyst Pharmaceuticals, Inc. (CPRX) | 441 | 0.00% | 50% |
| Pacific Biosciences of California, Inc. (PACB) | 440 | -0.29% | 44% |
| Abeona Therapeutics Inc. (ABEO) | 438 | +0.09% | 51% |
| KalVista Pharmaceuticals, Inc. (KALV) | 438 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.